BEST AVAILABLE COPY

FEB. 7. 2006 5:13PM

CLARK & ELBING

NO. 223 P. 8/10

RECEIVED
CENTRAL FAX CENTER

FEB 0 7 2006

PATENT

ATTORNEY DOCKET NO. 00786/247003

Certificate of Transmission by Facsimile: Date of Transmission: 2/7/04

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Examiner listed below at 1-571-273-8300, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated above.

Colleen Coune

Printed name of person transmitting facsimile

Colleer Corne

Signature of person transmitting facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Brian Seed et al.

Art Unit:

1648

Serial No.:

09/939,537

Examiner:

E. Le

Filed:

August 24, 2001

Customer No.:

21559

Title:

TARGETED CYTOLYSIS OF HIV-INFECTED CELLS BY

CHIMERIC CD4 RECEPTOR-BEARING CELLS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), The General Hospital Corporation, the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.

Pursuant to 37 C.F.R. § 1.321(b)(2), The General Hospital Corporation hereby

waives and disclaims the terminal portion of the term of the entire patent to be granted upon the application subsequent to the expiration date of U.S. Patent No. 6,753,162. The General Hospital Corporation does not disclaim any terminal part of any patent granted on the application prior to the expiration date of the full statutory term of U.S. Patent No. 6,753,162 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

Pursuant to 37 C.F.R. § 1.321(b)(3) and § 3.73(b), the undersigned attorney/agent of record certifies that The General Hospital Corporation, a corporation is the assignee of the entire right, title, and interest in the application by virtue of:

An assignment from the inventors of the application. The assignment was recorded in the Patent and Trademark Office at Reel/Frame 7290/0006 on November 28, 1994.

The undersigned attorney/agent of record has reviewed all the documents in the chain of title of the application and to the best of the undersigned's knowledge and belief, title is in The General Hospital Corporation.

Pursuant to 37 C.F.R. § 1.321(b)(4), Applicants authorize the Office to charge Deposit Account No. 03-2095 for \$130.00 for the fee set forth in 37 C.F.R. § 1.20(d).

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is being filed to overcome a double patenting rejection in the application. Any patent granted on the application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that the patent is commonly owned with the application or patent that formed the basis for the rejection.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 07 Februar 2006

Karen L. Elbing, Ph.D.

Reg. No. 35,238

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045